90%Confidence
0Views
FDASource
2026-03-29Date
Summary
Harbin Jixianglong's Semaglutide recall due to incomplete validation processes highlights significant regulatory compliance failures in the compounding pharmacy supply chain. This is particularly concerning given the high demand for Semaglutide and the potential for patient harm from improperly validated products.
Actionable: Immediately quarantine all Semaglutide products from this manufacturer and verify validation documentation for all compounding pharmacy suppliers.
AI Confidence: 90%
Data Points
firmHarbin Jixianglong Biotech Co., Ltd.
classificationClass II
statusOngoing
distributionNationwide within the United States
productSemaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-1
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now